Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astellas, Gilead, Mindmedicine, Minghui, Ocugen, Sunstone, Travere, Zenshine.
Additional early-stage research and drug discovery news in brief, from: Bioaegis Therapeutics, Evaxion Biotech, Jubilant Therapeutics, Sana Biotechnology.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, Airway, Altimmune, Bavarian, Chinook, Genexine, Hibio, Hotspot, Humacyte, Maia, Moderna, Paradigm, Quadriga.
Research at Pardes Biosciences Inc. has led to the identification of cysteine protease inhibitors, particularly 3C-like proteinase (3CLpro, Mpro, nsp5; SARS-CoV-2) and Mpro (HCoV-229E virus) inhibitors, reported to be useful for the treatment of viral infections.
As country after country downshifts out of pandemic mode, the need for affordable COVID-19 therapies continues, especially in middle-income countries that are not included in current voluntary licensing arrangements. To meet that need, the World Health Organization (WHO) is calling on manufacturers of those drugs to extend the geographic scope of their licensing agreements to allow competition and price reductions so the treatments can be used where they’re needed most.
Additional early-stage research and drug discovery news in brief, from: Alpha Cancer Technologies, Hillstream Biopharma, Tonix Pharmaceuticals Holding.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: ABVC, Aldeyra, Geovax, Astrocyte, Peptilogics, Quralis, Rallybio, Vega.
RSS
